Stock A063160 CKD BIO CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CKD Bio Corp.

Equities

A063160

KR7063160006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 20/05/2024 am IST 		5-day change 1st Jan Change
23,900 KRW -0.42% Intraday chart for CKD Bio Corp. -2.05% +0.21%
2023 CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 1,06,437 1,58,885 4,38,328 2,29,313 1,30,566
Enterprise Value (EV) 1 94,544 1,82,697 5,16,639 3,35,157 2,56,767
P/E ratio 13.4 x 13 x 69.6 x -34.9 x -7.82 x
Yield 0.96% 0.65% 0.25% 0.24% -
Capitalization / Revenue 0.85 x 1.16 x 3.52 x 1.61 x 0.84 x
EV / Revenue 0.76 x 1.33 x 4.15 x 2.36 x 1.65 x
EV / EBITDA 5.92 x 7.25 x 26 x 60.4 x 82.1 x
EV / FCF - -69,18,839 x -75,84,405 x -1,20,10,048 x -2,56,21,406 x
FCF Yield - -0% -0% -0% -0%
Price to Book 0.72 x 1 x 2.6 x 1.42 x 0.88 x
Nbr of stocks (in thousands) 5,386 5,386 5,486 5,486 5,486
Reference price 2 19,762 29,500 79,900 41,800 23,800
Announcement Date 12/03/20 12/03/20 18/03/21 17/03/22 14/03/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022
Net sales 1 1,24,510 1,37,184 1,24,600 1,42,238 1,56,042
EBITDA 1 15,965 25,189 19,842 5,552 3,128
EBIT 1 7,009 15,413 7,607 -11,432 -14,810
Operating Margin 5.63% 11.23% 6.11% -8.04% -9.49%
Earnings before Tax (EBT) 1 9,295 15,638 7,059 -13,358 -18,590
Net income 1 7,956 12,265 6,207 -6,577 -16,703
Net margin 6.39% 8.94% 4.98% -4.62% -10.7%
EPS 2 1,477 2,277 1,147 -1,199 -3,045
Free Cash Flow - -26,406 -68,119 -27,906 -10,022
FCF margin - -19.25% -54.67% -19.62% -6.42%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 190.5 190.5 200.0 100.0 -
Announcement Date 12/03/20 12/03/20 18/03/21 17/03/22 14/03/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2
Net sales 1 72.91
EBITDA -
EBIT 1 8.885
Operating Margin 12.19%
Earnings before Tax (EBT) -
Net income -
Net margin -
EPS -
Dividend per Share -
Announcement Date 31/01/20
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022
Net Debt 1 - 23,812 78,311 1,05,844 1,26,201
Net Cash position 1 11,893 - - - -
Leverage (Debt/EBITDA) - 0.9453 x 3.947 x 19.06 x 40.35 x
Free Cash Flow - -26,406 -68,119 -27,906 -10,022
ROE (net income / shareholders' equity) - 8.01% 3.79% -3.98% -10.8%
ROA (Net income/ Total Assets) - 4.61% 1.84% -2.46% -3.03%
Assets 1 - 2,66,026 3,37,395 2,67,853 5,51,387
Book Value Per Share 2 27,416 29,422 30,760 29,437 26,941
Cash Flow per Share 2 2,219 834.0 267.0 632.0 849.0
Capex 1 16,396 47,314 61,659 20,486 6,200
Capex / Sales 13.17% 34.49% 49.49% 14.4% 3.97%
Announcement Date 12/03/20 12/03/20 18/03/21 17/03/22 14/03/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CKD BIO CORP. Stock CKD Bio Corp.
+0.21% 96.4M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.35% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.49% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.15% 332B
ABBVIE INC. Stock AbbVie Inc.
+6.19% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.11% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 210B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+9.21% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A063160 Stock
  4. Financials CKD Bio Corp.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW